多药耐药相关蛋白1、谷胱甘肽S转移酶和DNA拓扑酶Ⅱ在骨肉瘤中的表达

Expression of multidrug resistance-associated protein 1,glutathione S transferase π and DNA topoiso meraseⅡin osteosarcoma

目的探讨骨肉瘤组织中多药耐药相关蛋白1(MRP1)、谷胱甘肽S转移酶(GST-π)和DNA拓扑酶Ⅱ(TopoⅡ)的表达及其与临床病理特征的关系。方法采用免疫组织化学方法检测10例正常成年骨组织和40例骨肉瘤组织中MRP1、GST-π和TopoⅡ的表达,并结合临床病理指标进行分析。结果10例正常骨组织和骨肉瘤中MRP1、GST-π和TopoⅡ阳性率分别为47.5%和0%、70.0%和20.0%、35.0%和80.0%(P<0.05),且随着骨肉瘤分化程度的降低,MRP1和GST-π表达率升高。根据肿瘤大小、患者性别、年龄及就诊前病程长短等分组,MRP1、GST-π和TopoⅡ表达无统计学意义,但与Enneking外科分期相关。结论骨肉瘤组织中有MRP1、GST-π和TopoⅡ的表达与骨肉瘤的恶性程度呈正相关,提示MRP1、GST-π和TopoⅡ可能为骨肉瘤原发耐药的重要原因之一。

Objective To study the expression of multidrug resistance-associated protein 1 （MRP1） ,glutathione S transferase π （GST-π） and DNA topoiso merase Ⅱ （Topo Ⅱ ） in human osteosarcoma,and its correlation with clinicopathologic characteristics.Methods Ten normal bone specimens and 40 osteosarcomas from patients were analysed tor MRP1 ,GST-π and Topo Ⅱ expression by immunohistochemistry. The expression levels of MRP1 ,GST-π and Topo Ⅱ with the clinicopathologic parameters of the patients were examined using Chi-square test. Results The positive expression rate of MRP1,GST-π and Topo Ⅱ were 47.5%, 70.0% and 35.0% in osteosarcoma. More specimens expressed Topo Ⅱ . MRP1 and GST-π in well-differentiated osteosarcomas than in poorly differentiated osteosarcomas. The expression of MRP1 ,GST-π and Topo Ⅱ was not related to the age and sex of the patients, osteosarcoma size, and duration before diagnosis,but it was related to Enneking surgical stage. Conclusion MRP1 ,GST-π and Topo Ⅱ are expressed in osteosarcoma and its expression is correlated with the malignancy of osteosarcoma.